Sangamo Therapeutics is a clinical-stage biopharmaceutical company that uses groundbreaking science to develop genomic medicines for patients suffering from diseases for which existing treatment options are inadequate or non-existent. The company's proprietary zinc finger genome engineering technology and manufacturing expertise enable it to create new genomic medicines with broad therapeutic potential. Sangamo's zinc finger (ZF) platform uniquely confers a number of advantages over other gene editing technologies. It is versatile, specific, and clinically useful. ZF technologies are composed of a DNA-binding domain that binds with precision to any sequence of DNA, and various functional domains (such as nucleases and transcription factors) that are based on therapeutic need. Due to their compact size, ZF technologies are highly vector compatible. This means that they can be paired with delivery vectors to create ZF-based genomic medicines.